Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 877 of 6351
-
New mammogram tech could spot hidden breast cancers in dense tissue
Diagnosis Recruiting nowTo learn whether a new imaging technology, Contrast-Enhanced Mammography (CEM), compared to standard mammography, can better detect breast cancers in women with dense breasts
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
New pill could quiet chronic cough that just Won't stop
Symptom relief OngoingThis is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Phase 3 • Sponsor: Bellus Health Inc. - a GSK company • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
New drug cocktail aims to wipe out breast cancer before surgery
Disease control OngoingAnlotinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that strongly inhibits VEGFR, PDGFR, FGFR, and c-kit. Combining anti-angiogenesis with chemotherapy yielded increased response rates in patients with early-stage human epidermal growth factor receptor 2 (HER2)-ne…
Phase 2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Immune cell levels may guide breast cancer treatment in new trial
Disease control OngoingThis study will assess if the presence of immune system cells in and around the tumor impacts tumor shrinkage in patients receiving neoadjuvant chemoimmunotherapy for triple-negative breast cancer.
Phase 2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Can a thyroid hormone rebuild failing hearts?
Disease control CompletedThis study aims to determine whether giving triiodothyronine (T3), a thyroid hormone, is safe and helps improve symptoms and signs of heart failure. Participants who are enrolled to receive the study drug will be admitted to the General Clinical Research Center (GCRC) for 5 days…
Phase 1 • Sponsor: Emory University • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Could a 66-cent pill replace CPAP for sleep apnea?
Disease control CompletedObstructive sleep apnea (OSA) is a severe type of snoring causing people to choke in their sleep. It affects millions of Americans, causing many health problems. For example, patients with OSA often feel very sleepy and are at risk of falling asleep while driving. OSA also causes…
Phase 2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New pacing technique could improve heart function in heart failure patients
Disease control Recruiting nowThe investigators aim to prospectively evaluate the efficacy and mechanism of benefit of His-bundle pacing enhanced cardiac resynchronization therapy (His-CRT) vs. cardiac resynchronization therapy (BIV-CRT) in patients with heart failure and right bundle branch block (RBBB).
Sponsor: University of Rochester • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Poop pills and a liquid diet: a new hope for kids with colitis?
Disease control Recruiting nowThis study included two topics: one was to test the efficacy and safety of fecal microbiota transplants plus partial enteral nutrition (PEN) in refractory pediatric UC where conventional therapy has failed, and the other was to explore the efficacy and safety of FMT plus PEN as f…
Sponsor: Biao Zou • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Promising combo aims to shrink esophageal tumors before surgery
Disease control OngoingChina with high incidence of esophageal cancer, the number of new cases and deaths account for about 50% of the world every year. In the past few decades, surgery, radiotherapy, chemotherapy and other treatments were continuously improved, however, the mortality of esophageal squ…
Phase 2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New scan could spot Alzheimer's hallmark before death
Diagnosis Recruiting nowThis study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathol…
Phase 3 • Sponsor: Lantheus Biosciences Ltd. • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
Blood test breakthrough could end painful spinal taps for dementia diagnosis
Diagnosis Recruiting nowThe diagnosis of diseases causing memory difficulties or dementia is often challenging. Without the use of advanced methods such as cerebrospinal fluid tests, approximately 25-30% do not receive a correct diagnosis today. However, the investigators have recently developed new blo…
Sponsor: Skane University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
New combo aims to wipe out hidden myeloma cells after transplant
Disease control Recruiting nowTo increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug balloon could keep leg arteries open longer
Disease control OngoingThis study aims to demonstrate the safety and efficacy of the SELUTION SLR™ 018 DEB compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA).
Sponsor: M.A. Med Alliance S.A. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New cocktail of drugs aims to tackle multiple myeloma early
Disease control Recruiting nowA Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-, Talquetamab-, and JNJ-79635322-based Combination Regimens in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma OBJECTIVES: To evaluate the safety and tolerability of teclistamab-, talquetamab-…
Phase 2 • Sponsor: University of Heidelberg Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Can a quick strike drug stop MS in its tracks?
Disease control Recruiting nowMultiple Sclerosis (MS) is a chronic inflammatory \& degenerative disease of the central nervous system (CNS) Recent data from the MS Base registry demonstrated an average delay of 152 - 215 days between first presentation and the diagnosis of MS, and more than one year until Dis…
Phase 2 • Sponsor: Queen Mary University of London • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Can a daily pill bring back skin color? new trial tests ritlecitinib for vitiligo
Disease control CompletedA 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug combo aims to shrink Hard-to-Treat colorectal tumors
Disease control OngoingThis is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in participants with refractory metastatic colorectal c…
Phase 2 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC
-
New drug SKB264 targets Hard-to-Treat cancers in Mid-Stage trial
Disease control OngoingThe purpose of this study is to assess the safety and efficacy of SKB264 monotherapy in subjects with selected advanced solid tumors.The study is divided into two parts: the Part Ⅰ consists of 5 cohorts, and the Part Ⅱ for expansion. Eligible subjects will receive SKB264 monother…
Phase 2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Veterans' suicide study tests new talk therapy
Disease control OngoingThe purpose of this project is to conduct a randomized control trial with 470 Veterans to examine the impact of a revised version of Motivational Interviewing to Address Suicidal Ideation (MI-SI-R) on risk for suicide attempts and suicidal ideation when compared to high quality u…
Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug eplontersen tested for Long-Term safety in heart disease patients
Disease control By invitation onlyThe purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.
Phase 3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC